- Home
- BCIC vs PRQR Comparison
BCIC vs PRQR Comparison
Compare BCIC & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCIC | PRQR |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 173.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | BCIC | PRQR |
|---|---|---|
| Price | $12.29 | $1.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.14 |
| AVG Volume (30 Days) | 75.5K | ★ 569.1K |
| Earning Date | 03-05-2026 | 11-06-2025 |
| Dividend Yield | ★ 15.40% | N/A |
| EPS Growth | ★ 330.32 | N/A |
| EPS | ★ 1.64 | N/A |
| Revenue | ★ $58,080,000.00 | $18,859,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.87 | $18.44 |
| P/E Ratio | $7.52 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.12 | $1.07 |
| 52 Week High | $17.51 | $3.10 |
Technical Indicators
Market Signals| Indicator | BCIC | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 35.01 |
| Support Level | N/A | $1.58 |
| Resistance Level | N/A | $1.71 |
| Average True Range (ATR) | 0.00 | 0.16 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 12.23 |
Price Performance
Historical ComparisonAbout BCIC BCP Investment Corporation
BCP Investment Corp is a closed-end, externally managed, non-diversified management investment company. The company invests in performing, well- established middle market businesses that operate across a wide range of industries. It employs fundamental credit analysis, targeting investments in businesses with relatively low levels of cyclicality and operating risk.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.